01.13.16
inVentiv Health has opened its new Phase I clinic in the U.S., located at the University of Miami Life Science and Technology Park.
The services provided at this facility will complement the Phase I through Phase IV clinical capabilities offered at the company's existing bioanalytical labs.
"The Miami clinic is purpose-built to optimize trials for clients from the start," said Michael McKelvey, president, inVentiv Health Clinical Division and executive vice president, inVentiv Health. "Everything from the location, to the pioneering processes we will use to enroll patients, to the ability to inject market access knowledge into the design strategy from the earliest phases of development, is intended to help clients improve trial execution, speed time to market and reduce development costs."
The Miami clinic will facilitate patient, special populations and normal healthy volunteer access to research for clients focused on complex studies, including first-in-human Phase I, Phase I-in-patient and other multifaceted Phase I trials such as drug-drug interaction, biosimilar, first-to-file and 505b2 trials.
The services provided at this facility will complement the Phase I through Phase IV clinical capabilities offered at the company's existing bioanalytical labs.
"The Miami clinic is purpose-built to optimize trials for clients from the start," said Michael McKelvey, president, inVentiv Health Clinical Division and executive vice president, inVentiv Health. "Everything from the location, to the pioneering processes we will use to enroll patients, to the ability to inject market access knowledge into the design strategy from the earliest phases of development, is intended to help clients improve trial execution, speed time to market and reduce development costs."
The Miami clinic will facilitate patient, special populations and normal healthy volunteer access to research for clients focused on complex studies, including first-in-human Phase I, Phase I-in-patient and other multifaceted Phase I trials such as drug-drug interaction, biosimilar, first-to-file and 505b2 trials.